CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
CVI Accepts, published online ahead of print on 19 December 2007
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00379-07v1
15/3/447    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by VANCUTSEM, E.
Right arrow Articles by NAESSENS, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by VANCUTSEM, E.
Right arrow Articles by NAESSENS, A.
Clin. Vaccine Immunol. doi:10.1128/CVI.00379-07
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Production of recombinant antigens of Ureaplasma parvum serotype 3 and 6 for the development of a serological assay

E. VANCUTSEM*, F. ECHAHIDI, K. VAN GEEL, G. MUYLDERMANS, O. SOETENS, and A. NAESSENS

Universitair Ziekenhuis Brussel, Department: Microbiology, Laarbeeklaan 101, 1090 Jette (Belgium) and VIRCO BVBA, Generaal De Wittelaan L11 B4, 2800 Mechelen (Belgium)

* To whom correspondence should be addressed. Email: Ellen.Vancutsem{at}uzbrussel.be.


   Abstract

Recombinant antigens of Ureaplasma parvum serotypes 3 and 6 were produced in order to develop a serological assay for Ureaplasma antibody detection. The genes of the multiple banded antigen (MBA) were amplified with PCR and cloned in a pTrcHis TOPO plasmid. Purified recombinant proteins were evaluated in Western blot and ELISA with monoclonal antibodies and human sera.

Our approach was successful in the production of the recombinant MBA (rMBA) for serotypes 3 and 6. The antigens tested positive with serotype specific monoclonal antibodies in Western blot and in ELISA. Prominent reactions were detected with the recombinant multiple banded antigen (rMBA) and their homologous monoclonal antibodies. Strong cross reactions were visible in ELISA between the rMBA 3 and the monoclonal antibodies from the other U. parvum serotypes. A weak cross reaction was seen with the rMBA 3 and the monoclonal antibody from serotype 4. The rMBA 6 showed only cross reaction with the monoclonal antibody from U. parvum serotype 1. Fifty one percent of the sera obtained from culture positive women, reacted with one or both rMBAs. Only 3 (15%) of the sera from culture negative women reacted with the rMBA. These positive reactions were only observed with rMBA 6. These preliminary tests showed the potential usefulness of the produced rMBAs for detecting an antibody response against Ureaplasma antigens.







Home Help [Feedback] [For Subscribers] [Archive] [Search] --
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.